» Articles » PMID: 9679986

Expression of Signal Transducers and Activators of Transcription Proteins in Acute Myeloid Leukemia Blasts

Overview
Journal Cancer Res
Specialty Oncology
Date 1998 Jul 29
PMID 9679986
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Hematopoietic cytokine receptor signaling pathways involve activation of signal transducers and activators of transcription (STAT) proteins, which are postulated to be involved in cellular differentiation. Aberrant STAT isoforms (beta forms rather than the normal alpha forms) have been described and have been found to block the normal signaling pathway from the receptor. Bcr/Abl proteins have been suggested to directly activate STATs, without exposure to growth factors. We asked whether STATs play a role in leukemogenesis. We analyzed constitutive and induced patterns of STAT activity in pretreatment blasts from 36 newly diagnosed acute myeloid leukemia (AML) patients and studied protein tyrosine kinases (PTKs) that may be involved in STAT activity, using in vitro and in-gel kinase assays. The beta forms were expressed in 21 of 27 samples (78%). Constitutive STAT3 and STAT5 activity was found in samples from 28 and 22% of patients, respectively. Response to exogenous cytokines identified two groups. STAT activity in one group was modulated by exogenous cytokines: constitutive STAT activity increased in some patients but decreased or disappeared in response to cytokines in others. The second group was cytokine insensitive. Additionally, we found constitutive PTK activity in two patients whose blasts demonstrated constitutive STAT activity, suggesting that PTKs use cytokine receptor signal pathways to activate STATs in AML blasts without exposure to exogenous cytokines. Our data suggest that (a) constitutive expression of aberrant STATs may be involved in blocking differentiation of AML blasts, (b) exogenous cytokines may activate STAT-inhibitory pathways, and (c) STATs may be activated by PTKs in some AML blasts.

Citing Articles

STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes.

King Z, Desai S, Frank D, Shastri A Neoplasia. 2025; 61:101137.

PMID: 39933227 PMC: 11869857. DOI: 10.1016/j.neo.2025.101137.


Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review).

Cheng H, Chen L, Huang C Oncol Lett. 2025; 29(3):134.

PMID: 39822941 PMC: 11737296. DOI: 10.3892/ol.2025.14881.


IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.

Yang J, Chen J, Chang J, Sun X, Wei Q, Cai X Cell Commun Signal. 2024; 22(1):116.

PMID: 38347540 PMC: 10863291. DOI: 10.1186/s12964-023-01367-y.


The Pt(-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.

Silconi Z, Rosic V, Benazic S, Radosavljevic G, Mijajlovic M, Pantic J Int J Mol Sci. 2022; 23(15).

PMID: 35897737 PMC: 9332548. DOI: 10.3390/ijms23158161.


The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia.

Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D Biomedicines. 2021; 9(8).

PMID: 34440253 PMC: 8392322. DOI: 10.3390/biomedicines9081051.